Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP

JAMA1 Aug 2016Cited by 576 (Europe PMC)

PMID27483064PMCIDPMC5021525DOI10.1001/jama.2016.10260PepBankPUB-27483064

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients recently hospitalized with heart failure and reduced LVEF, liraglutide had no significant effect on the global rank score of clinical stability versus placebo.
In plain wordsIn patients with advanced heart failure, liraglutide did not improve clinical stability more than placebo.
Peptide
Liraglutide
Outcome
No significant changeGlobal rank score (primary end point)
Study
n = 300
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Measurements
Mean rank
146 rank
liraglutide
Mean rank
156 rank
placebo
Source sentences
Summary
Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31).
2 context sentences(design, population, supporting numbers)
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306401
02HumanRandomized controlled trialEfficacy outcome
In patients with advanced heart failure, liraglutide showed no significant difference from placebo for the exploratory secondary end points.
In plain wordsIn patients with advanced heart failure, liraglutide did not differ from placebo on the exploratory outcomes.
Peptide
Liraglutide
Outcome
No significant changeExploratory secondary end points
Study
n = 300
Comparator
Placebo
Analysis
Exploratory
Outcome group
Heart function · Cardiovascular
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Source sentences
Summary
There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0…
3 context sentences(design, population, supporting numbers)
Summary · context
Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events.
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306404
03HumanRandomized controlled trialEfficacy outcome
In patients with advanced heart failure, deaths did not differ significantly between liraglutide and placebo.
In plain wordsIn patients with advanced heart failure, liraglutide did not change the number of deaths compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeDeaths
Study
n = 300
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Measurements
Hazard ratio, death
1.1 HR
liraglutide vs placebo
Source sentences
Summary
There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0…
2 context sentences(design, population, supporting numbers)
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306402
04HumanRandomized controlled trialEfficacy outcome
In patients with advanced heart failure, rehospitalizations for heart failure did not differ significantly between liraglutide and placebo.
In plain wordsIn patients with advanced heart failure, liraglutide did not change hospital readmissions for heart failure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeRehospitalization for heart failure
Study
n = 300
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Measurements
Hazard ratio, rehospitalization
1.3 HR
liraglutide vs placebo
Source sentences
Summary
There were no significant between-group differences in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0…
2 context sentences(design, population, supporting numbers)
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306403
05HumanRandomized controlled trialSafety outcome
In patients with advanced heart failure, hyperglycemic events were numerically fewer with liraglutide than with placebo; the abstract reports no test.
In plain wordsIn patients with advanced heart failure, fewer high blood sugar events were reported with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
DecreaseInvestigator-reported hyperglycemic events
Study
n = 300
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Measurements
Hyperglycemic events
16 patients
liraglutide
Hyperglycemic events
27 patients
placebo
Source sentences
Summary
The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306406
06HumanRandomized controlled trialSafety outcome
In patients with advanced heart failure, hypoglycemic events were infrequent and numerically fewer with liraglutide than with placebo; the abstract reports no test.
In plain wordsIn patients with advanced heart failure, low blood sugar events were rare and slightly fewer with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
DecreaseHypoglycemic events
Study
n = 300
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Measurements
Hypoglycemic events
2 patients
liraglutide
Hypoglycemic events
4 patients
placebo
Source sentences
Summary
The number of investigator-reported hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306407
07HumanRandomized controlled trialEfficacy outcome
In patients with heart failure and diabetes, prespecified subgroup analyses showed no significant difference between liraglutide and placebo.
In plain wordsIn heart failure patients with diabetes, liraglutide did not differ from placebo in the subgroup analyses.
Peptide
Liraglutide
Outcome
No significant changePrimary and secondary outcomes in patients with diabetes (subgroup)
Study
n = 178
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
up to 1.8 mg/d · subcutaneous · 180 daysAs given in this study (human).
Source sentences
Summary
Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences.
2 context sentences(design, population, supporting numbers)
Summary · context
Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized.
Summary · context
The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.
Report a problemFND-2748306405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01800968

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Duke Universityn = 300Apr 2013 to Oct 2015

Acute Heart Failure

Trial page ClinicalTrials.govUpdated 15 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.